GE signs up to make Blue Earth cancer imaging agent

Prostate cancer (Courtesy of Michael Bonert [CC BY-SA 3.0])
Prostate cancer (Courtesy of Michael Bonert [CC BY-SA 3.0])
GE Healthcare has signed up to produce Blue Earth Diagnostics’ positron-emission tomography (PET) imaging product in the United Kingdom. The deal moves Blue Earth a step closer to making its recently approved prostate cancer agent available in its home country.

Oxford, U.K.-based Blue Earth won a European marketing authorization for its synthetic L-leucine analogue radiolabeled with fluorine 18 agent earlier this year. That regulatory nod recognized the scope for the imaging agent, branded Axumin, to make it easier for doctors to differentiate tumors from healthy tissues. This differentiation is particularly important when biomarker changes suggest the cancer has recurred but the tumor is invisible to older imaging techniques.

Blue Earth responded to the receipt of a European regulatory recommendation for Axumin in March by stepping up discussions with manufacturers and distributors. That led to an agreement with Axumin covering France, Germany, Ireland, Italy, Portugal and Spain. And now to the U.K. pact with GE, the company Blue Earth spun out of 2014.

Read more on fiercebiotech.com

Search

Sign Up to Our Newsletter